Given the exceptional β2AR selectivity and ceiling effect of PAMs, Cmpd-6 may improve the pharmacological treatment of asthma and other respiratory diseases by increasing the bronchoprotective response to β2-agonists, lowering the effective dose of β2-agonists, and producing fewer side effects. This evidence concerns the gene ADRB2 and respiratory system disorder.